AR069290A1 - Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden - Google Patents
Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprendenInfo
- Publication number
- AR069290A1 AR069290A1 ARP080104932A ARP080104932A AR069290A1 AR 069290 A1 AR069290 A1 AR 069290A1 AR P080104932 A ARP080104932 A AR P080104932A AR P080104932 A ARP080104932 A AR P080104932A AR 069290 A1 AR069290 A1 AR 069290A1
- Authority
- AR
- Argentina
- Prior art keywords
- hgm
- csf
- macrofagos
- granulocitos
- colony
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Con una capacidad de neutralizacion suficiente a la actividad de hGM-CSF. Asimismo, se proporcionan composiciones farmacéuticas que comprenden dicho anticuerpo o fragmento de union al antígeno, su ADN, uso y método para producirlo. La presente solicitud es util para el tratamiento de varias enfermedades que están asociadas con la expresion aberrante de hGM-CSF. Reivindicacion 1: Un anticuerpo monoclonal anti hGM-CSF aislado o fragmento de union al antígeno del mismo, en donde el anticuerpo o fragmento de union al antígeno del mismo une un epítopo de hGM-CSF (SEC ID N° 1) que comprende ELYK (SEC ID N° 2) y TMMASHYKQH (SEC ID N° 3).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007294945 | 2007-11-13 | ||
| JP2008052471 | 2008-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069290A1 true AR069290A1 (es) | 2010-01-13 |
Family
ID=40329216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104932A AR069290A1 (es) | 2007-11-13 | 2008-11-12 | Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8679502B2 (es) |
| EP (3) | EP2535353A1 (es) |
| KR (1) | KR20100102108A (es) |
| CN (2) | CN101970489B (es) |
| AR (1) | AR069290A1 (es) |
| AU (1) | AU2008321429A1 (es) |
| BR (1) | BRPI0820530A2 (es) |
| CA (1) | CA2705539A1 (es) |
| CL (1) | CL2008003361A1 (es) |
| CO (1) | CO6382188A2 (es) |
| DK (1) | DK2215119T3 (es) |
| EC (1) | ECSP10010251A (es) |
| ES (1) | ES2401536T3 (es) |
| HR (1) | HRP20130204T1 (es) |
| IL (1) | IL205576A0 (es) |
| MA (1) | MA31899B1 (es) |
| ME (1) | ME01005B (es) |
| MX (1) | MX2010005291A (es) |
| NZ (2) | NZ586027A (es) |
| PE (1) | PE20091420A1 (es) |
| PL (1) | PL2215119T3 (es) |
| PT (1) | PT2215119E (es) |
| RS (1) | RS52713B (es) |
| RU (2) | RU2517596C2 (es) |
| SG (1) | SG176499A1 (es) |
| SI (1) | SI2215119T1 (es) |
| TN (1) | TN2010000210A1 (es) |
| TW (2) | TW201206955A (es) |
| UY (1) | UY31466A1 (es) |
| WO (1) | WO2009064399A1 (es) |
| ZA (1) | ZA201003467B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| US20110044996A1 (en) * | 2007-05-23 | 2011-02-24 | Charles Mackay | Neutralizing antibodies |
| WO2009062238A1 (en) * | 2007-11-12 | 2009-05-22 | Crc For Asthma And Airways Ltd | Epitope for neutralizing antibodies |
| PT2215119E (pt) | 2007-11-13 | 2013-02-11 | Boehringer Ingelheim Int | Anticorpos monoclonais que se ligam a hgm-csf e composições médicas que os compreendem |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| MX2011002558A (es) | 2008-09-10 | 2011-04-26 | Boehringer Ingelheim Int | Terapia de combinacion para el tratamiento de diabetes y estados relacionados. |
| CA2747206C (en) | 2008-12-22 | 2018-04-24 | The University Of Melbourne | Pain treatment |
| PL2376121T5 (pl) | 2008-12-22 | 2021-09-27 | The University Of Melbourne | Leczenie zapalenia kości i stawów |
| KR20220025926A (ko) | 2010-06-24 | 2022-03-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| JP2014520784A (ja) | 2011-07-06 | 2014-08-25 | モルフォシス・アー・ゲー | 抗ｃｄ２０抗体と抗ｇｍ−ｃｓｆ抗体との治療的組合せおよびその使用 |
| MY175388A (en) * | 2012-09-20 | 2020-06-23 | Morphosys Ag | Treatment for rheumatoid arthritis |
| AR093297A1 (es) * | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| EP2914289B1 (en) | 2012-10-31 | 2019-05-22 | Takeda GmbH | Lyophilized formulation comprising gm-csf neutralizing compound |
| WO2014138862A1 (en) * | 2013-03-14 | 2014-09-18 | John Schrader | Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof |
| WO2015028657A1 (en) | 2013-08-30 | 2015-03-05 | Takeda Gmbh | Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics |
| ES2974895T3 (es) | 2014-05-07 | 2024-07-02 | Takeda Pharmaceuticals Co | Formulación líquida que comprende un compuesto neutralizante de GM-CSF |
| EP3368561B1 (en) * | 2015-10-30 | 2025-09-17 | Medimmune Limited | Prevention of n-terminal truncation in igg light chains |
| KR101953706B1 (ko) | 2016-09-19 | 2019-03-05 | 아이-맵 | 항-gm-csf 항체 및 이것의 사용 |
| JP7399852B2 (ja) * | 2017-06-25 | 2023-12-18 | システィミューン， インク． | 多重特異性抗体とその作製及び使用方法 |
| AU2018396964C1 (en) * | 2017-12-28 | 2024-10-03 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against PD-L1 |
| EP3623382A1 (en) * | 2018-09-14 | 2020-03-18 | Universität Zürich | Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct |
| US11655293B2 (en) * | 2018-02-22 | 2023-05-23 | Universitat Zurich | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
| JP7686563B2 (ja) * | 2019-02-08 | 2025-06-02 | ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド | 皮膚、毛髪、爪および／または粘膜の処置および／またはケアに有用な化合物 |
| WO2025221669A1 (en) * | 2024-04-18 | 2025-10-23 | Promab Biotechnologies, Inc. | Fusion protein comprising il-12 and gm-csf |
| CN120399067B (zh) * | 2025-07-02 | 2025-09-30 | 武汉伊莱瑞特生物科技股份有限公司 | 一种与人gm-csf特异性结合的单克隆抗体及其检测试剂盒和应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8624899D0 (en) * | 1986-10-17 | 1986-11-19 | Sandoz Ltd | Monoclonal antibodies |
| EP0452315A1 (en) * | 1988-05-31 | 1991-10-23 | Schering Biotech Corporation | Method of treating myeloid leukemias |
| NZ234479A (en) | 1989-07-14 | 1992-03-26 | Schering Corp | Antagonists of gm-csf derived from the carboxyl terminus, antibodies, hybridomas and pharmaceutical compositions containing anti-idiotypic antibodies |
| GB8925590D0 (en) * | 1989-11-13 | 1990-01-04 | Central Blood Lab Authority | Monoclonal antibodies |
| US6713610B1 (en) * | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| AU8910891A (en) | 1990-11-20 | 1992-06-11 | National Heart & Lung Institute, The | Treatment of lung diseases |
| CA2060741A1 (en) | 1991-02-11 | 1992-08-12 | Robert S. Greenfield | Gm-csf inhibiting oligopeptides |
| US5833987A (en) * | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
| BR9606706A (pt) * | 1995-10-16 | 1999-04-06 | Unilever Nv | Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo |
| US5662138A (en) * | 1996-06-12 | 1997-09-02 | Wang; Wen-Hsing | Drop head structure |
| US7455836B2 (en) * | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
| KR20060088905A (ko) * | 2000-06-16 | 2006-08-07 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 면역특이적으로 ＢＬｙＳ에 결합하는 항체 |
| CA2422730A1 (en) * | 2000-09-19 | 2002-03-28 | Microbia, Inc. | Modulation of secondary metabolite production by zinc binuclear cluster proteins |
| PE20021080A1 (es) | 2001-04-12 | 2003-02-12 | Boehringer Ingelheim Int | Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer |
| US7084257B2 (en) * | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| WO2003040341A2 (en) * | 2001-11-07 | 2003-05-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anti-hepatitis a virus antibodies |
| JP2006500905A (ja) * | 2002-02-13 | 2006-01-12 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | ヒト化ｇｍ−ｃｓｆ抗体 |
| US7193069B2 (en) * | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| US7361740B2 (en) * | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| US20070254836A1 (en) | 2003-12-03 | 2007-11-01 | Defrees Shawn | Glycopegylated Granulocyte Colony Stimulating Factor |
| UA89364C2 (en) | 2003-12-03 | 2010-01-25 | Биодженерикс Аг | Granulocyte colony stimulating factor peptide conjugate (g-csf) |
| DE602004021773D1 (de) | 2004-05-05 | 2009-08-13 | Micromet Ag | Herstellung eines einkettigen fv Antikörperfragments |
| WO2006011353A1 (ja) | 2004-07-30 | 2006-02-02 | Thk Co., Ltd. | ねじ溝加工方法 |
| CN101184777B (zh) * | 2005-04-18 | 2013-07-17 | 安进研发（慕尼黑）股份有限公司 | 人粒细胞巨噬细胞集落刺激因子的抗体中和剂 |
| PL3620171T3 (pl) * | 2005-05-18 | 2022-08-08 | Morphosys Ag | Przeciwciała anty-gm-csf i ich zastosowania |
| JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| HRP20170024T1 (hr) * | 2006-02-08 | 2017-03-10 | Morphotek, Inc. | Antigeni peptidi gm-csf i protutijela protiv gm-csf |
| CN101605547A (zh) | 2006-11-21 | 2009-12-16 | 卡罗拜奥斯制药公司 | 使用gm-csf拮抗剂治疗慢性炎症疾病的方法 |
| US8398972B2 (en) * | 2006-11-21 | 2013-03-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a GM-CSF antagonist |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| PT2215119E (pt) | 2007-11-13 | 2013-02-11 | Boehringer Ingelheim Int | Anticorpos monoclonais que se ligam a hgm-csf e composições médicas que os compreendem |
-
2008
- 2008-11-12 PT PT88486964T patent/PT2215119E/pt unknown
- 2008-11-12 ME MEP-2010-89A patent/ME01005B/me unknown
- 2008-11-12 RU RU2010123693/10A patent/RU2517596C2/ru not_active IP Right Cessation
- 2008-11-12 AR ARP080104932A patent/AR069290A1/es not_active Application Discontinuation
- 2008-11-12 KR KR1020107012568A patent/KR20100102108A/ko not_active Ceased
- 2008-11-12 CN CN200880124664.1A patent/CN101970489B/zh not_active Expired - Fee Related
- 2008-11-12 UY UY31466A patent/UY31466A1/es not_active Application Discontinuation
- 2008-11-12 MX MX2010005291A patent/MX2010005291A/es active IP Right Grant
- 2008-11-12 SI SI200830911T patent/SI2215119T1/sl unknown
- 2008-11-12 EP EP12181684A patent/EP2535353A1/en not_active Withdrawn
- 2008-11-12 RS RS20130035A patent/RS52713B/sr unknown
- 2008-11-12 HR HRP20130204AT patent/HRP20130204T1/hr unknown
- 2008-11-12 CL CL2008003361A patent/CL2008003361A1/es unknown
- 2008-11-12 PL PL08848696T patent/PL2215119T3/pl unknown
- 2008-11-12 US US12/681,396 patent/US8679502B2/en active Active
- 2008-11-12 DK DK08848696.4T patent/DK2215119T3/da active
- 2008-11-12 NZ NZ586027A patent/NZ586027A/en not_active IP Right Cessation
- 2008-11-12 PE PE2008001912A patent/PE20091420A1/es not_active Application Discontinuation
- 2008-11-12 CN CN201410203384.7A patent/CN104072613A/zh active Pending
- 2008-11-12 CA CA2705539A patent/CA2705539A1/en not_active Abandoned
- 2008-11-12 TW TW100141459A patent/TW201206955A/zh unknown
- 2008-11-12 ES ES08848696T patent/ES2401536T3/es active Active
- 2008-11-12 NZ NZ597023A patent/NZ597023A/xx not_active IP Right Cessation
- 2008-11-12 EP EP12192975A patent/EP2559706A1/en not_active Withdrawn
- 2008-11-12 AU AU2008321429A patent/AU2008321429A1/en not_active Abandoned
- 2008-11-12 EP EP08848696A patent/EP2215119B1/en active Active
- 2008-11-12 TW TW097143709A patent/TWI434854B/zh not_active IP Right Cessation
- 2008-11-12 SG SG2011085453A patent/SG176499A1/en unknown
- 2008-11-12 WO PCT/US2008/012680 patent/WO2009064399A1/en not_active Ceased
- 2008-11-12 BR BRPI0820530-2A patent/BRPI0820530A2/pt not_active IP Right Cessation
-
2010
- 2010-05-06 IL IL205576A patent/IL205576A0/en unknown
- 2010-05-12 TN TN2010000210A patent/TN2010000210A1/fr unknown
- 2010-05-17 ZA ZA2010/03467A patent/ZA201003467B/en unknown
- 2010-06-03 MA MA32889A patent/MA31899B1/fr unknown
- 2010-06-11 CO CO10070935A patent/CO6382188A2/es active IP Right Grant
- 2010-06-14 EC EC2010010251A patent/ECSP10010251A/es unknown
-
2013
- 2013-09-09 RU RU2013141223/10A patent/RU2013141223A/ru not_active Application Discontinuation
-
2014
- 2014-01-28 US US14/166,803 patent/US20140205611A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069290A1 (es) | Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden | |
| CL2020002305A1 (es) | Uso de anticuerpos sirpa v1 antihumanos y procedimiento de producción de anticuerpos anti-sirpa v1 | |
| EA202191580A1 (ru) | Биспецифичные антитела анти-cd28 x анти-cd22 и их применение | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| EA201990781A9 (ru) | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
| CY1119454T1 (el) | Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος | |
| CR20190440A (es) | Receptores de unión a antígeno mejorados | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| JOP20210265A1 (ar) | الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها | |
| BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
| AR106570A1 (es) | Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos | |
| EA201590613A1 (ru) | Антитела против cd3, биспецифические антигенсвязывающие молекулы, которые связываются с cd3 и cd20, и их применения | |
| UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
| EA201290570A1 (ru) | Конструкты, связывающиеся с ron, и способы их использования | |
| CO6710903A2 (es) | Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| AR078470A1 (es) | Anticuerpos que se unen especificamente al receptor epha2 | |
| JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
| CY1119539T1 (el) | Πληρως ανθρωπινα αντισωματα ειδικα για to cadμ1 | |
| AR067199A1 (es) | Proteinas de union a antigenos que se unen a par-2 | |
| EA202090372A1 (ru) | Универсальные соединения авт и их применение | |
| BR112018072681A2 (pt) | anticorpos anti-il-1r3 humanizados | |
| PE20200927A1 (es) | Anticuerpos monoclonales que se unen a la region de la cadena beta de la familia trbv9 del receptor de las celulas t humanas | |
| UA113623C2 (uk) | Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi) | |
| EA202193309A1 (ru) | Конъюгаты антитело к тканевому фактору-лекарственное средство и связанные способы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |